Morgan Stanley
ABCL icon

Morgan Stanley’s AbCellera Biologics ABCL Stock Holding History

Morgan Stanley’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1M Sell
1,669,014
-555,815
-25% -$2.72M ﹤0.01% 3477
2026
Q1 		$7.76M Sell
2,224,829
-777,021
-26% -$2.8M ﹤0.01% 3786
2025
Q4 		$10.3M Buy
3,001,850
+209,708
+8% +$936K ﹤0.01% 3587
2025
Q3 		$14M Buy
2,792,142
+1,795,215
+180% +$7.91M ﹤0.01% 3241
2025
Q2 		$3.42M Sell
996,927
-294,089
-23% -$732K ﹤0.01% 4358
2025
Q1 		$2.88M Buy
1,291,016
+353,631
+38% +$1.01M ﹤0.01% 4360
2024
Q4 		$2.75M Buy
937,385
+347,732
+59% +$968K ﹤0.01% 4467
2024
Q3 		$1.53M Buy
589,653
+37,523
+7% +$104K ﹤0.01% 4798
2024
Q2 		$1.63M Buy
552,130
+161,991
+42% +$613K ﹤0.01% 4678
2024
Q1 		$1.77M Buy
390,139
+13,249
+4% +$67.6K ﹤0.01% 4665
2023
Q4 		$2.15M Sell
376,890
-204,525
-35% -$948K ﹤0.01% 4462
2023
Q3 		$2.67M Sell
581,415
-600,731
-51% -$3.65M ﹤0.01% 4198
2023
Q2 		$7.64M Buy
1,182,146
+272,742
+30% +$1.86M ﹤0.01% 3424
2023
Q1 		$6.86M Buy
909,404
+273,870
+43% +$2.49M ﹤0.01% 3498
2022
Q4 		$6.44M Sell
635,534
-67,476
-10% -$779K ﹤0.01% 3510
2022
Q3 		$6.95M Buy
703,010
+224,007
+47% +$2.46M ﹤0.01% 3353
2022
Q2 		$5.1M Buy
479,003
+85,867
+22% +$727K ﹤0.01% 3743
2022
Q1 		$3.83M Sell
393,136
-107,834
-22% -$1.02M ﹤0.01% 3965
2021
Q4 		$7.17M Sell
500,970
-235,049
-32% -$3.57M ﹤0.01% 3329
2021
Q3 		$14.8M Buy
736,019
+161,826
+28% +$2.86M ﹤0.01% 2427
2021
Q2 		$12.6M Buy
574,193
+501,828
+693% +$13.8M ﹤0.01% 2711
2021
Q1 		$2.46M Buy
72,365
+69,415
+2,353% +$2.77M ﹤0.01% 4102
2020
Q4 		$118K Buy
+2,950
New +$135K ﹤0.01% 5841

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Morgan Stanley's ABCL Position: Q2 2026 in Review

Morgan Stanley reduced its AbCellera Biologics (ABCL) stake by 25% in Q2 2026, selling an estimated $2.72M and leaving 1,669,014 shares worth $13.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3477.

Morgan Stanley first reported a position in ABCL in Q4 2020 and has held it in 23 quarters since. The position peaked at $14.8M in Q3 2021. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Morgan Stanley held 1,669,014 shares of AbCellera Biologics worth $13.1M as of Q2 2026.
  • Morgan Stanley sold 555,815 AbCellera Biologics shares in Q2 2026, an estimated $2.72M.
  • AbCellera Biologics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3477 holding.
  • Morgan Stanley first reported a position in AbCellera Biologics in Q4 2020 and has held it in 23 quarters since.
  • Morgan Stanley's AbCellera Biologics position peaked at $14.8M in Q3 2021.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.